22 November, 2016 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Brad Hoy, Chief Financial Officer (CFO), and Dr Craig Fox, Chief Scientific Officer (CSO), will join the Board of Directors with immediate effect. In addition, Brad Hoy has been appointed permanent CFO today following a period as interim CFO.
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that the Company has entered into a multi-target, risk-sharing alliance ("the Agreement") with Evotec AG ("Evotec"), a leading drug discovery alliance and development partnership company. The new Agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small molecule drugs across a range of targets, therapeutic areas and stages of development, with the initial programmes targeted towards the treatment of cancer and autoimmune diseases.
Calculus Capital Limited and Polar Capital LLP to join share register
C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery engine, today announces that it has raised £5.0 million before expenses (the "Placing") via a conditional placing of 4,901,961 new ordinary shares (the "Placing Shares") to current and new investors, through Zeus Capital as nominated adviser and broker to the Company, at a placing price of 102p (the “Placing Price”) per ordinary share.
Proprietary platform technology further augments C4X Discovery’s drug discovery engine
12th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the acquisition of a suite of advanced drug-discovery technologies from MolPlex Ltd (the "Molplex Technologies").
~ Rapid progress with drug discovery portfolio and ground-breaking findings in inflammation and neurodegeneration ~
4th July, 2016 - C4X Discovery Holdings plc (AIM: C4XD), an innovative drug discovery and development company, today announces the identification of multiple new drug targets in the areas of inflammation and neurodegeneration.